Patents by Inventor BENJAMIN ROSSI

BENJAMIN ROSSI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LEUCOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR NEUTRALIZING ANTIBODIES
    Publication number: 20220025056
    Abstract: This invention relates to agents that bind and neutralize the inhibitory activity of human ILT2 proteins having inhibitory activity in NK cells, T cells and/or other immune cells. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 27, 2022
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • Multispecific antigen binding proteins
    Patent number: 11208480
    Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: December 28, 2021
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Benjamin Rossi
  • SIGLEC NEUTRALIZING ANTIBODIES
    Publication number: 20210363249
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: STEPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • VARIABLE REGIONS FOR NKP46 BINDING PROTEINS
    Publication number: 20210269523
    Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: May 10, 2021
    Publication date: September 2, 2021
    Inventors: LAURENT GAUTHIER, NADIA ANCERIZ, ARIANE MOREL, BENJAMIN ROSSI
  • Siglec-10 antibodies
    Patent number: 11083785
    Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 10, 2021
    Assignee: INNATE PHARMA
    Inventors: Stephanie Cornen, Laurent Gauthier, Benjamin Rossi, Nicolai Wagtmann
  • Siglec neutralizing antibodies
    Patent number: 11078274
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: August 3, 2021
    Assignee: INNATE PHARMA
    Inventors: Stephanie Cornen, Benjamin Rossi, Nicolai Wagtmann
  • Variable regions for NKp46 binding proteins
    Patent number: 11001629
    Abstract: NKp-46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: May 11, 2021
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER
    Publication number: 20200369764
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 26, 2020
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • SIGLEC-9-NEUTRALIZING ANTIBODIES
    Publication number: 20200369765
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 26, 2020
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN, LAURENT GAUTHIER
  • KIR3DL2 BINDING AGENTS
    Publication number: 20200199228
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB
  • NKp46 BINDING PROTEINS
    Publication number: 20200131268
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 30, 2020
    Inventors: Laurent GAUTHIER, Nadia ANCERIZ, Ariane MOREL, Benjamin ROSSI
  • KIR3DL2 binding agents
    Patent number: 10577419
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: March 3, 2020
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
  • MULTISPECIFIC ANTIGEN BINDING PROTEINS
    Publication number: 20200048345
    Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: June 23, 2016
    Publication date: February 13, 2020
    Inventors: Laurent GAUTHIER, Benjamin ROSSI
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20200024357
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 23, 2020
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • NKp46 binding proteins
    Patent number: 10519234
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: December 31, 2019
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20190389961
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: March 16, 2018
    Publication date: December 26, 2019
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS
    Publication number: 20190218308
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • POTENTIATING THE EFFECT OF ATP RELEASE
    Publication number: 20190218304
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 in the treatment of cancer to potentiate the activity of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
  • KIR3DL2 binding agents
    Patent number: 10246510
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: April 2, 2019
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Benjamin Rossi, Hélène Sicard, Carine Paturel
  • SIGLEC NEUTRALIZING ANTIBODIES
    Publication number: 20190085077
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 21, 2019
    Inventors: STEPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN